Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220616 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
A Phase 1 study of Hematological Malignancies, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 420
- Enrollment target
- 4
- Study locations
NCT07220616 is a Phase 1 study of Hematological Malignancies that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 420 participants, below the 750-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT07220616, a Phase 1 study of Hematological Malignancies, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 420 participants
- Enrollment target
- 4
- Study locations
Study Summary
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Conditions Studied
Interventions
- DRUG DS3790a
- DRUG Combination drug
Study Locations (4)
Other
- Aichi Cancer Center Hospital - Nagoya
- Research Site - Tokyo
- Research Site - Tokyo
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220616
The ClinicalTrials.gov registry entry for NCT07220616 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (44% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 2 interventions - of which DS3790a is the first listed.
NCT07220616 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT07220616 about?
NCT07220616 is a clinical study titled "A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies". This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
What is the current status of trial NCT07220616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2026-01-16. Estimated completion is 2030-11-30.
What conditions does trial NCT07220616 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT07220616?
The interventions under investigation include: DS3790a (DRUG), Combination drug (DRUG).
Who is sponsoring clinical trial NCT07220616?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220616 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study of AZD9829 in CD123+ Hematological Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.